8EZ1

Human Ornithine Aminotransferase (hOAT) co-crystallized with its inactivator 3-Amino-4-fluorocyclopentenecarboxylic Acid


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.91 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.189 
  • R-Value Observed: 0.191 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Structural and Mechanistic Basis for the Inactivation of Human Ornithine Aminotransferase by (3 S ,4 S )-3-Amino-4-fluorocyclopentenecarboxylic Acid.

Shen, S.Butrin, A.Beaupre, B.A.Ferreira, G.M.Doubleday, P.F.Grass, D.H.Zhu, W.Kelleher, N.L.Moran, G.R.Liu, D.Silverman, R.B.

(2023) Molecules 28

  • DOI: https://doi.org/10.3390/molecules28031133
  • Primary Citation of Related Structures:  
    8EZ1

  • PubMed Abstract: 

    Ornithine aminotransferase (OAT) is overexpressed in hepatocellular carcinoma (HCC), and we previously showed that inactivation of OAT inhibits the growth of HCC. Recently, we found that (3 S ,4 S )-3-amino-4-fluorocyclopentenecarboxylic acid ( 5 ) was a potent inactivator of γ-aminobutyric acid aminotransferase (GABA-AT), proceeding by an enamine mechanism. Here we describe our investigations into the activity and mechanism of 5 as an inactivator of human OAT. We have found that 5 exhibits 10-fold less inactivation efficiency ( k inact / K I ) against h OAT than GABA-AT. A comprehensive mechanistic study was carried out to understand its inactivation mechanism with h OAT. p K a and electrostatic potential calculations were performed to further support the notion that the α,β-unsaturated alkene of 5 is critical for enhancing acidity and nucleophilicity of the corresponding intermediates and ultimately responsible for the improved inactivation efficiency of 5 over the corresponding saturated analogue ( 4 ). Intact protein mass spectrometry and the crystal structure complex with h OAT provide evidence to conclude that 5 mainly inactivates h OAT through noncovalent interactions, and that, unlike with GABA-AT, covalent binding with h OAT is a minor component of the total inhibition which is unique relative to other monofluoro-substituted derivatives. Furthermore, based on the results of transient-state measurements and free energy calculations, it is suggested that the α,β-unsaturated carboxylate group of PLP-bound 5 may be directly involved in the inactivation cascade by forming an enolate intermediate. Overall, compound 5 exhibits unusual structural conversions which are catalyzed by specific residues within h OAT, ultimately leading to an enamine mechanism-based inactivation of h OAT through noncovalent interactions and covalent modification.


  • Organizational Affiliation

    Department of Chemistry and Center for Developmental Therapeutics, Northwestern University, Evanston, IL 60208, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Ornithine aminotransferase, mitochondrial
A, B, C
404Homo sapiensMutation(s): 0 
Gene Names: OAT
EC: 2.6.1.13
UniProt & NIH Common Fund Data Resources
Find proteins for P04181 (Homo sapiens)
Explore P04181 
Go to UniProtKB:  P04181
PHAROS:  P04181
GTEx:  ENSG00000065154 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP04181
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
X8H (Subject of Investigation/LOI)
Query on X8H

Download Ideal Coordinates CCD File 
E [auth B](1R,3S,4Z)-3-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-4-iminocyclopentane-1-carboxylic acid
C14 H19 N2 O7 P
CTOWFYUCLIAQOJ-XPIHRMQRSA-N
X8B (Subject of Investigation/LOI)
Query on X8B

Download Ideal Coordinates CCD File 
D [auth A],
F [auth C]
(3E,4E)-4-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-3-iminocyclopent-1-ene-1-carboxylic acid
C14 H15 N2 O7 P
NSAJRPMHFRLIPA-LEGHTLSWSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.91 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.189 
  • R-Value Observed: 0.191 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 202.17α = 90
b = 110.29β = 103.72
c = 57.12γ = 90
Software Package:
Software NamePurpose
PHENIXmodel building
PHENIXrefinement
xia2data reduction
Aimlessdata scaling
xia2data reduction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United States--

Revision History  (Full details and data files)

  • Version 1.0: 2023-02-22
    Type: Initial release
  • Version 1.1: 2023-10-25
    Changes: Data collection, Refinement description
  • Version 1.2: 2024-03-13
    Changes: Source and taxonomy